BR170720

BR170720 is an investigational small molecule atypical antipsychotic developed by Shandong Bainuo Pharmaceutical for the treatment of schizophrenia. It functions as a multi-receptor modulator, acting as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and as an antagonist at serotonin 5-HT2A receptors. This pharmacological profile is intended to provide efficacy against both positive and negative symptoms of schizophrenia while reducing the risk of extrapyramidal side effects and metabolic complications. BR170720 is classified as a Class 1 innovative drug in China and is currently undergoing Phase 2 clinical trials to evaluate its safety and efficacy in patients with schizophrenia.